Incyte Corp
Change company Symbol lookup
Select an option...
INCY Incyte Corp
MATX Matson Inc
TECK Teck Resources Ltd
BCBNF Base Carbon Inc
PAVM PAVmed Inc
HTGC Hercules Capital Inc
NRG NRG Energy Inc
NLTX Neoleukin Therapeutics Inc
AROW Arrow Financial Corp
EQ Equillium Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Closing Price
$78.19
Day's Change
3.41 (4.56%)
Bid
--
Ask
--
B/A Size
--
Day's High
78.30
Day's Low
75.23
Volume
(Heavy Day)
Volume:
2,298,161

10-day average volume:
1,540,364
2,298,161

INCY's position in the Biotechnology industry

Industry PeersINCYAMGNREGNAPLSCCXI

Summary

Company ProfileIncyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products...
Go to AMGN summary
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines...
Go to REGN summary
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The...
Go to APLS summary
ChemoCentryx, Inc. is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. The Company is targeting the...
Go to CCXI summary
52-Week Change

VS. INDUSTRY
-9.95%
1.11%
11.25%
-26.57%
89.91%
Market Cap

VS. INDUSTRY
$17.3B
$131.1B
$67.3B
$4.9B
$1.9B
Beta

VS. INDUSTRY
0.7
0.6
0.3
1.6
1.9
Dividend Yield

VS. INDUSTRY
--
3.16%
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
18.61x
24.16x
8.68x
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$3.1B
$26.3B
$16.5B
$80.9M
$27.3M
Profit Margin

VS. INDUSTRY
29.96%
21.75%
48.06%
-866.81%
-514.64%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
51.40%
0.08%
56.36%
--
--
Revenue Growth (TTM)

VS. INDUSTRY
15.24%
4.58%
79.48%
-67.71%
-60.53%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.